Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, and represents a significant global health burden with rising incidence rates, despite a more thorough understanding of the etiology and biology of HCC, as well as advancements in diagnosis and treatment modalities. According to emerging evidence, imaging features related to tumor aggressiveness can offer relevant prognostic information, hence validation of imaging prognostic features may allow for better noninvasive outcomes prediction and inform the selection of tailored therapies, ultimately improving survival outcomes for patients with HCC.
Hepatoblastoma is the most common pediatric liver malignancy and usually occurs within the first 3 years of life. In recent years, the overall incidence of hepatoblastoma has exhibited the greatest increase among all pediatric malignancies worldwide. The diagnosis of hepatoblastoma may be challenging due to the lack of a current consensus classification system. The International Pediatric Liver Tumors Consensus introduced guidelines and a consensus classification for the diagnosis of hepatoblastoma as either epithelial or mixed epithelial and mesenchymal and in the updated 5th edition of the World Health Organization Classification of Digestive System Tumors.
Citations
Citations to this article as recorded by
Tumor‐associated macrophages: The key player in hepatoblastoma microenvironment and the promising therapeutic target Ahmad Adawy, Yoshihiro Komohara, Taizo Hibi Microbiology and Immunology.2024; 68(8): 249. CrossRef
Hepatoblastoma: A Case Report Abel Ning Caballero, Kandecy Archer-Austin Asploro Journal of Biomedical and Clinical Case Reports.2024; 7(3): 226. CrossRef
Adult Hepatoblastoma and Concomitant Hepatitis B Infection Alejandro Nieto Dominguez, Sarah Elizabeth Eichinger, Elza Matrova, Anas Almoghrabi ACG Case Reports Journal.2024; 11(9): e01491. CrossRef
Metabolic and Epigenetic Mechanisms in Hepatoblastoma: Insights into Tumor Biology and Therapeutic Targets Yuanji Fu, Raquel Francés, Claudia Monge, Christophe Desterke, Agnès Marchio, Pascal Pineau, Yunhua Chang-Marchand, Jorge Mata-Garrido Genes.2024; 15(11): 1358. CrossRef
Adult hepatoblastoma: making the challenging distinction from hepatocellular carcinoma Allison Kaye L. Pagarigan, Paulo Giovanni L. Mendoza Journal of Liver Cancer.2023; 23(1): 219. CrossRef
Advances in Histological and Molecular Classification of Hepatocellular Carcinoma Joon Hyuk Choi, Swan N. Thung Biomedicines.2023; 11(9): 2582. CrossRef
Jae Won Song, Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Young Nyun Park, Dai Hoon Han, Do Young Kim
J Liver Cancer. 2021;21(1):69-75. Published online March 31, 2021
Hepatocellular carcinoma (HCC) primarily originates in the liver with hepatic differentiation. However, HCCs are not homogenous, and approximately 35% of HCC cases are classified as histopathological variants that present distinct pathologic characteristics. In particular, the lymphocyte-rich variant is the rarest subtype accounting for less than 1% of HCCs, which is not well known to date about molecular features and pathophysiology. Herein, we present a case of a patient who was suspected of metastatic liver cancer and confirmed as lymphocyte-rich HCC pathologically. A 78-year-old woman who underwent a right hemicolectomy for colon cancer was referred to our hospital for a newly detected liver mass. We could not make a decision because of insufficient evidence for diagnosis from imaging studies. After resection, we found that it was a lymphocyte-rich HCC. The pathologic features and prognostic trends of this subtype are also discussed.
Citations
Citations to this article as recorded by
Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures Bokyung Ahn, Hee‐Sung Ahn, Jinho Shin, Eunsung Jun, Eun‐Young Koh, Yeon‐Mi Ryu, Sang‐Yeob Kim, Chang Ohk Sung, Ju Hyun Shim, JeongYeon Hong, Kyunggon Kim, Hyo Jeong Kang Liver International.2024; 44(5): 1202. CrossRef
Uncommon variants of hepatocellular carcinoma: Not one size fits all Reetu Kundu, Nalini Gupta, Debajyoti Chatterjee, Ajay Duseja Diagnostic Cytopathology.2022; 50(1): 28. CrossRef